Incyte Bolsters Hematology Pipeline with Vega Therapeutics Acquisition

What happened

Incyte completed the acquisition of Vega Therapeutics, a subsidiary of Star Therapeutics, adding an early-stage hematology asset to its portfolio. The deal aligns with Incyte's diversification strategy ahead of the 2028 Jakafi patent cliff but financial terms were undisclosed and the asset is preclinical, offering no near-term revenue. The acquisition does little to address the heavy dependence on Jakafi and Opzelura, which together generate the vast majority of sales. At a rich ~45x EV/EBITDA and with crowded bullish sentiment, this bolt-on is unlikely to shift the risk-reward profile. Investors should focus on Opzelura growth and tafasitamab progress as the true catalysts.

Implication

The Vega acquisition adds to Incyte's hematology pipeline but provides no near-term revenue inflection, leaving the stock vulnerable to any Opzelura or Jakafi guidance disappointment. Given the rich valuation and crowded sentiment, we see asymmetric downside risk. Investors should wait for a more attractive entry point near $90 or for stronger evidence that Opzelura and tafasitamab can fill the Jakafi gap. The deal does not alter our POTENTIAL SELL rating or the 6-12 month re-assessment window.

Thesis delta

The acquisition incrementally supports Incyte's long-term portfolio diversification but does not affect the core thesis that the stock is overvalued given the 2028 ruxolitinib LOE and execution risks on Opzelura and tafasitamab. The deal is too small and early-stage to change the probability-weighted base case of $105 or the bear case of $80. We continue to see more downside than upside from the current $107 level.